Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DQ8S | ISIN: US6904691010 | Ticker-Symbol: 1OT
Tradegate
06.06.25 | 17:27
0,280 Euro
+0,72 % +0,002
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OVID THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
OVID THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2700,29006.06.
0,2660,29006.06.

Aktuelle News zur OVID THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoOvid Therapeutics Inc.: Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025-
OVID THERAPEUTICS Aktie jetzt für 0€ handeln
13.05.Ovid Therapeutics GAAP EPS of -$0.14 in-line, revenue of $0.13M beats by $0.1M3
13.05.Ovid Therapeutics Inc. - 10-Q, Quarterly Report2
13.05.Ovid Therapeutics Inc. - 8-K, Current Report2
02.05.Ovid Therapeutics Inc. - 8-K, Current Report2
24.03.BTIG cuts Ovid Therapeutics stock price target to $42
11.03.Ovid Therapeutics Inc. - 10-K, Annual Report-
11.03.Ovid Therapeutics GAAP EPS of -$0.13 beats by $0.03, revenue of $0.07M misses by $0.12M1
05.03.Ovid Therapeutics Inc. - 8-K, Current Report-
03.03.Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors3
13.02.Ovid Therapeutics Inc. - 8-K, Current Report-
11.09.24Ovid Therapeutics Inc.: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth452NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions...
► Artikel lesen
13.08.24Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results404Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded Scientific Advisory Board under the leadership of Dr....
► Artikel lesen
01.07.24Ovid Therapeutics Inc.: Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations176The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse eventsSecondary endpoint results indicate that the target...
► Artikel lesen
17.06.24Ovid Therapeutics Inc.: Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat1.136Takeda's Skyline study in Dravet syndrome narrowly missed its primary endpoint of reduction in convulsive seizure frequency and showed clinically meaningful and significant effects in multiple key...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1